Health Condition 1: M049- Autoinflammatory syndrome, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Sponsors
ALEXE RAJAN
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria for patients All consecutive patients of rheumatoid arthritis ( satisfying the ACR/EULAR 2012 classification criteria ) presenting to the rheumatology OPD will be recruited in the study after written informed consent. Age should be more than 18 years old. Treatment naive patients or patients who received less than or equal to 10 mg prednisolone for last 1 month or patients on suboptimal dose of DMARDs in last month will be considered (under the discretion of rheumatologist). Inclusion criteria for controls Age more than 18 years. No history of smoking. Willingness to participate in study.
Exclusion criteria
Exclusion criteria: Exclusion criteria for patients Concomitant infections or malignancies Smokers Patients on DMARDs within the last 3 months , patients on prednisolone for more than 1 month. Other diseases which can affect the value of MMP9 and A1AT like SLE, psoriatic arthritis , ankylosing spondylitis , reactive arthritis , juvenile idiopathic arthritis , Sjogren’s syndrome) Chronic infections (bacterial,viral,fungal) Pregnant patients will be excluded Exclusion criteria for controls Concomitant infections or malignancies Smokers Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The study expects to prove MMP9 and A1AT ratio can be used as a reliable biomarker to predict the prognosis of each RA patients by reflecting on the dynamic imbalance between MMP9 and A1AT component which are primarily responsible for joint destruction. The study may prove the baseline and serial MMP9and A1AT ratio can be an indicator for expected joint damage in RA cases over long run. Timepoint: Baseline levels will be estimated when a patient is diagnosed with Rheumatoid Arthritis. after 3 months the level of MMP9 and A1AT will be estimated again , followed by 6th month and on 9th month from first day of diagnosis. . The obtained values will be used to calculate the ratio on each visit . the USG7 scan will only be done on day of diagnosis followed by 9th month. | — |
Secondary
| Measure | Time frame |
|---|---|
| The MMP9 & A1AT ratio can be used as indicator for predicting non-responders to treatment. MMP9 to A1AT ratio at baseline can be used to predict the disease progression at long run.Timepoint: the ratio has to be reduced at 3 months compared to the day of diagnosis, then 6th month should be less than 3 months so on if the patient is responding to the treatment . | — |
Countries
India
Contacts
Public ContactDr Ravindra Maradi
Kasturba Medical College , Manipal
Outcome results
None listed